Tykerb (lapatinib) — United Healthcare
Central Nervous System (CNS) Cancers
Initial criteria
- One of the following:
- (1) All of the following:
- Diagnosis of recurrent CNS cancer with metastatic lesions
- AND Tykerb is active against primary (breast) tumor
- AND Used in combination with Xeloda (capecitabine)
- OR
- (2) All of the following:
- Diagnosis of progressive or recurrent intracranial or spinal ependymoma (excluding subependymoma)
- AND Patient has received previous radiation therapy
- AND One of the following:
- Patient has received gross total or subtotal resection with negative CSF cytology
- OR Patient has received subtotal resection and evidence of metastasis (brain, spine, or CSF)
- OR Patient has unresectable disease
- AND Used in combination with Temodar (temozolomide)
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Tykerb therapy
Approval duration
12 months